Section Review Central & Peripheral Nervous Systems: α1-Adrenoceptor antagonists as treatments for benign prostatic hyperplasia
暂无分享,去创建一个
[1] P. Insel,et al. Comparison of cloned and pharmacologically defined rat tissue α1-adrenoceptor subtypes , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.
[2] K. Tveter,et al. alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. , 1995, The Journal of urology.
[3] I. Marshall,et al. Noradrenaline contractions of human prostate mediated by α1c‐(α1c‐) adrenoceptor subtype , 1995 .
[4] A. Naylor,et al. Characterization of an α1D‐adrenoceptor mediating the contractile response of rat aorta to noradrenaline , 1995, British journal of pharmacology.
[5] T. Branchek,et al. Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. , 1995, Journal of medicinal chemistry.
[6] A. Ford,et al. Functional evidence equating the pharmacologically‐defined α1A‐ and cloned α1C‐adrenoceptor: studies in the isolated perfused kidney of rat , 1995 .
[7] G. Tsujimoto,et al. Cloning, functional expression and tissue distribution of human α 1C‐adrenoceptor splice variants , 1995, FEBS letters.
[8] A. Goetz,et al. Characterization of alpha-1 adrenoceptor subtypes in human and canine prostate membranes. , 1994, The Journal of pharmacology and experimental therapeutics.
[9] M. Wyllie,et al. Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. , 1994, Urology.
[10] A. Ford,et al. α1-Adrenoceptor classification: sharpening Occam's razor , 1994 .
[11] T. Branchek,et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. , 1994, Molecular pharmacology.
[12] G. Vallancien,et al. Identification of α1-adrenoceptor subtypes present in the human prostate , 1994 .
[13] H. Lepor,et al. The alpha‐adrenoceptor subtype mediating the tension of human prostatic smooth muscle , 1993, The Prostate.
[14] C. Chapple,et al. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. , 1993, European urology.
[15] K. Sudoh,et al. Effect of the optical isomers of YM-12617 on increased intra-urethral pressure induced by phenylephrine in anaesthetized dogs. , 1992, Journal of autonomic pharmacology.
[16] K. Kawabe,et al. Use of an α1-Blocker, YM617, in the Treatment of Benign Prostatic Hypertrophy , 1990 .
[17] J. McNeal,et al. Pathology of benign prostatic hyperplasia. Insight into etiology. , 1990, The Urologic clinics of North America.
[18] I. Muramatsu,et al. Pharmacological subclassification of α1‐adrenoceptors in vascular smooth muscle , 1990 .
[19] D. Loury,et al. Identification of a single α1‐adrenoceptor corresponding to the α1A‐subtype in rat submaxillary gland , 1989 .
[20] G. Burnstock,et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. , 1989, British journal of urology.
[21] M. Dunn,et al. Indoramin--an effective new drug in the management of bladder outflow obstruction. , 1987, British journal of urology.
[22] N. Flavahan,et al. α1-Adrenoceptor subclassification in vascular smooth muscle , 1986 .
[23] J. Hieble,et al. In vitro characterization of the alpha-adrenoceptors in human prostate. , 1985, European journal of pharmacology.
[24] E. Yokoyama,et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. , 1982, The Journal of urology.